Bacterial sepsis – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Sat, 08 Aug 2026 04:43:21 +0000 en-US hourly 1 https://wordpress.org/?v=7.1 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Bacterial sepsis – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Individualized beta‑lactam dosing with piperacillin (drug combination) for ICU patients with sepsis caused by gram‑negative bacteria https://clinicaltrials.eu/trial/individualized-beta-lactam-dosing-with-piperacillin-drug-combination-for-icu-patients-with-sepsis-caused-by-gram-negative-bacteria/ Sat, 08 Aug 2026 04:43:21 +0000 https://clinicaltrials.eu/trial/individualized-beta-lactam-dosing-with-piperacillin-drug-combination-for-icu-patients-with-sepsis-caused-by-gram-negative-bacteria/ Patients with sepsis in the intensive care unit often receive antibiotics from the beta-lactam class, such as piperacillin, tazobactam, amoxicillin, cefotaxime, cefepime, ceftazidime, avibactam and meropenem. Sepsis is a serious condition where the body’s response to infection can damage its own organs, and prompt, effective antibiotic treatment is crucial.

The study aims to determine whether an individualized approach that combines therapeutic drug monitoring, minimal inhibitory concentration and model-based dose adjustment can improve outcomes for these patients. Therapeutic drug monitoring means measuring the amount of antibiotic in the blood, minimal inhibitory concentration is the lowest drug level that stops bacterial growth, and model-based dose adjustment uses computer calculations to set the right dose.

Participants will be randomly assigned to receive the standard antibiotic regimen or the individualized regimen. In the individualized group, blood samples are taken shortly after the infusion to check drug levels, and doses may be modified based on the results. Patients are followed for up to 28 days to record time spent in the intensive care unit, need for breathing support or kidney treatment, and survival, without any additional procedures beyond routine care.

]]> Study of vitamin D3 (cholecalciferol) as additional treatment for elderly patients with pneumonia or sepsis due to infection https://clinicaltrials.eu/trial/study-of-vitamin-d3-cholecalciferol-as-additional-treatment-for-elderly-patients-with-pneumonia-or-sepsis-due-to-infection/ Mon, 03 Aug 2026 10:38:59 +0000 https://clinicaltrials.eu/trial/study-of-vitamin-d3-cholecalciferol-as-additional-treatment-for-elderly-patients-with-pneumonia-or-sepsis-due-to-infection/ This clinical trial investigates the effects of high-dose vitamin D3 (cholecalciferol) in elderly patients who are hospitalized with either pneumonia or sepsis. Pneumonia is a lung infection that can be seen on chest x-rays, while sepsis is a serious condition where the body has an extreme response to an infection that can be life-threatening.

The study tests whether giving additional vitamin D3 along with standard treatment can help patients leave the hospital sooner or reduce inflammation in the body. Participants will receive either vitamin D3 solution (DIBASE) or placebo in the form of refined olive oil. The treatment will be given by mouth and can last up to 12 months.

The research focuses on measuring how well patients recover during their hospital stay, including how quickly they can be discharged and whether they need intensive care. The study will also track changes in substances in the blood that show inflammation levels, particularly proteins called IL-6 and C-reactive protein. Patients will be monitored for up to 90 days to assess their recovery and any effects of the treatment.

]]> Evaluation of Optimized Ceftazidime Dosing Regimen Versus Standard Treatment for Critical Care Patients with Sepsis https://clinicaltrials.eu/trial/evaluation-of-optimized-ceftazidime-dosing-regimen-versus-standard-treatment-for-critical-care-patients-with-sepsis/ Mon, 03 Aug 2026 10:38:49 +0000 https://clinicaltrials.eu/trial/evaluation-of-optimized-ceftazidime-dosing-regimen-versus-standard-treatment-for-critical-care-patients-with-sepsis/ This clinical trial evaluates a new dosing approach for ceftazidime, an antibiotic medication used to treat sepsis. Sepsis is a serious condition that occurs when the body’s response to an infection damages its own tissues and organs, potentially leading to organ failure and death if not treated promptly. The study aims to compare an optimized ceftazidime dosing regimen with the standard regimen in patients receiving critical care.

The trial focuses on finding the best way to administer ceftazidime to quickly reach and maintain effective medication levels in the bloodstream of critically ill patients. Participants will be adults in critical care units who have infections requiring ceftazidime treatment. During the study, researchers will monitor medication levels in the blood at specific time points after administration to determine if the optimized regimen achieves target concentrations more effectively than standard dosing.

The study will also track patients’ organ function using a special assessment tool, monitor for potential side effects such as seizures or altered consciousness, and evaluate kidney function throughout the treatment period. This research could lead to improved antibiotic dosing strategies for critically ill patients with sepsis.

]]>